| 1 |
Complementary Pharmacokinetic Profiles of Netupitant and Palonosetron Support the Rationale for Their Oral Fixed Combination for the Prevention of Chemotherapy-Induced Nausea and Vomiting |
|
|
| James Gilmore,Alberto Bernareggi |
|
| The Journal of Clinical Pharmacology. 2019; 59(4): 472 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 2 |
Doxorubicin-Induced Myocardial Fibrosis Involves the Neurokinin-1 Receptor and Direct Effects on Cardiac Fibroblasts |
|
|
| Scott P. Levick,David R. Soto-Pantoja,Jianli Bi,W. Gregory Hundley,Alexander Widiapradja,Edward J. Manteufel,Tancia W. Bradshaw,Giselle C. Meléndez |
|
| Heart, Lung and Circulation. 2018; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 3 |
Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-?B axis: Shedding new light on resistance to Aprepitant |
|
|
| Davood Bashash,Ava Safaroghli-Azar,Samaneh Bayati,Elham Razani,Atieh Pourbagheri-Sigaroodi,Arshia Gharehbaghian,Majid Momeny,Maryam Sanjadi,Mostafa Rezaie-Tavirani,Seyed H. Ghaffari |
|
| The International Journal of Biochemistry & Cell Biology. 2018; 103: 105 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 4 |
Application of analytical quality by design principles for the determination of alkyl p -toluenesulfonates impurities in Aprepitant by HPLC. Validation using total-error concept |
|
|
| Constantinos K. Zacharis,Elli Vastardi |
|
| Journal of Pharmaceutical and Biomedical Analysis. 2018; 150: 152 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 5 |
Treatment of nausea with innovative antiemetics |
|
|
| Yuki Fujii,Hanae Ida,Tatsushi Shimokuni,Fumihiko Haraguchi |
|
| Expert Review of Quality of Life in Cancer Care. 2017; 2(2): 109 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 6 |
Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients |
|
|
| Michelle C Janelsins,Mohamedtaki A Tejani,Charles Kamen,Anita R Peoples,Karen M Mustian,Gary R Morrow |
|
| Expert Opinion on Pharmacotherapy. 2013; 14(6): 757 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 7 |
Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients |
|
|
| Janelsins, M.C. and Tejani, M.A. and Kamen, C. and Peoples, A.R. and Mustian, K.M. and Morrow, G.R. |
|
| Expert Opinion on Pharmacotherapy. 2013; 14(6): 757-766 |
|
| [Pubmed] [Google Scholar] |
|
| 8 |
Use of high-dose cisplatin with aprepitant in an outpatient setting |
|
|
| Furukawa, N. and Kawaguchi, R. and Kobayashi, H. |
|
| European Journal of Cancer Care. 2012; 21(4): 436-441 |
|
| [Pubmed] [Google Scholar] |
|
| 9 |
Ondansetron in combination with gingerol suppresses cisplatin-induced pica in rats |
|
|
| Yang, Y.-L. and Yue, W. and Tian, Z.-B. and Wang, M.-L. and Yang, Z.-H. and Zhang, Q. and Wei, L.-Z. and Zhao, Q.-X. and Shi, Z.-Y. |
|
| World Chinese Journal of Digestology. 2011; 19(10): 1034-1039 |
|
| [Pubmed] [Google Scholar] |
|
| 10 |
Use of high-dose cisplatin with aprepitant in an outpatient setting : Management of high-dose cisplatin administration |
|
|
| N. FURUKAWA, R. KAWAGUCHI, H. KOBAYASHI |
|
| European Journal of Cancer Care. 2011; : no |
|
| [HTML Full text] [Google Scholar] [DOI] |
|
| 11 |
Chemotherapy-Induced Nausea and Vomiting: Challenges and Opportunities for Improved Patient Outcomes |
|
|
| Hawkins, R. and Grunberg, S. |
|
| Clinical Journal of Oncology Nursing. 2009; 13(1): 54-64 |
|
| [Pubmed] [Google Scholar] |
|
| 12 |
Pharmacological Management of Chemotherapy-Induced Nausea and Vomiting in Children with Cancer |
|
|
| M.G. Cefalo,A. Ruggiero,P. Maurizi,G. Attiną,A. Arlotta,R. Riccardi |
|
| Journal of Chemotherapy. 2009; 21(6): 605 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 13 |
Pharmacological management of chemotherapy-induced nausea and vomiting in children with cancer |
|
|
| Cefalo, M.G., Ruggiero, A., Maurizi, P., Attiną, G., Arlotta, A., Riccardi, R. |
|
| Journal of Chemotherapy. 2009; 21(6): 605-610 |
|
| [Pubmed] [Google Scholar] |
|
| 14 |
Pharmacological Characterization of T-2328, 2-Fluoro-4ę-methoxy-3ę-[[[(2S,3S)-2-phenyl-3-piperidinyl]amino]methyl]-[1,1ę-biphenyl]-4-carbonitrile Dihydrochloride, as a Brain-Penetrating Antagonist of Tachykinin NK1 Receptor |
|
|
| Yumi Watanabe,Hidetoshi Asai,Taketoshi Ishii,Satoko Kiuchi,Masahito Okamoto,Hiroyuki Taniguchi,Masaaki Nagasaki,Akira Saito |
|
| Journal of Pharmacological Sciences. 2008; 106(1): 121 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 15 |
Pharmacological Characterization of T-2328, 2-Fluoro-4ę-methoxy-3ę-[[[(2S, 3S)-2-phenyl-3-piperidinyl] amino] methyl]-[1, 1ę-biphenyl]-4-carbonitrile Dihydrochloride, as a Brain-Penetrating Antagonist of Tachykinin NK 1 Receptor |
|
|
| Watanabe, Y. and Asai, H. and Ishii, T. and Kiuchi, S. and Okamoto, M. and Taniguchi, H. and Nagasaki, M. and Saito, A. |
|
| Journal of Pharmacological Sciences. 2008; 106(1): 121-127 |
|
| [Pubmed] [Google Scholar] |
|
| 16 |
Aprepitant - Where do we stand in the control of chemotherapy-induced nausea and vomiting? |
|
|
| Sarcev, T., Secen, N., Zaric, B., Milovancev, A. |
|
| Journal of B.U.ON.. 2008; 13(3): 333-339 |
|
| [Pubmed] [Google Scholar] |
|
| 17 |
Substance P and its receptors--a potential target for novel medicines in malignant brain tumour therapies (mini-review) |
|
|
| Neuropeptides, M. and Warsaw, P., Łazarczyk, M., Matyja, E., Lipkowski, A. |
|
| Folia Neuropathologica. 2007; 45(3): 99-107 |
|
| [Pubmed] [Google Scholar] |
|
